Loading company…
Synthekine develops engineered cytokine therapies for oncology and autoimmune diseases.
Founded in 2018 and based in Menlo Park, US, Synthekine develops engineered cytokine therapeutics, including partial agonists and surrogate agonists, for oncology and autoimmune diseases. Its programs include SYNCAR-001 and STK-009. In December 2022, it raised USD 150.00 mn in Series C funding led by The Column Group.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in